Optionsscheine finden
Nähere Informationen zum Handelssegment EASY EUWAX finden Sie hier.
► Tipp: Abonnieren Sie unsere Newsletter, um immer auf dem Laufenden bei aktuellen Wertpapierentwicklungen zu bleiben.
Ihre Auswahl:
112 Ergebnisse
| JE8Z1S | Halozyme Therapeutics Inc./OS/Call [100]/JPMD | - | - | 100,000 | call | Halozyme Therapeutics Inc. | - | 52,318 % | 0,353 | -0,023 | 5,296 | 18.12.2026 | 0,100 | JP Morgan | ||
| MM26P7 |  | Halozyme Therapeutics Inc./OS/Call [100]/MS | - | - | 100,000 | call | Halozyme Therapeutics Inc. | - | 50,712 % | 0,348 | -0,022 | 5,464 | 18.12.2026 | 0,100 | Morgan Stanley | |
| MM2SE4 | | Halozyme Therapeutics Inc./OS/Call [100]/MS | - | - | 100,000 | call | Halozyme Therapeutics Inc. | - | - | - | - | - | 17.06.2027 | 0,100 | Morgan Stanley | |
| MM5J62 | | Halozyme Therapeutics Inc./OS/Call [100]/MS | - | - | 100,000 | call | Halozyme Therapeutics Inc. | - | 60,110 % | 0,244 | -0,035 | 8,029 | 18.09.2026 | 0,100 | Morgan Stanley | |
| MN0311 | | Halozyme Therapeutics Inc./OS/Call [100]/MS | - | - | 100,000 | call | Halozyme Therapeutics Inc. | - | - | - | - | - | 17.12.2027 | 0,100 | Morgan Stanley | |
| MN6DYJ | | Halozyme Therapeutics Inc./OS/Call [100]/MS | - | - | 100,000 | call | Halozyme Therapeutics Inc. | - | 50,036 % | 0,416 | -0,019 | 4,237 | 19.03.2027 | 0,100 | Morgan Stanley | |
| MM8H8T | | Halozyme Therapeutics Inc./OS/Call [105]/MS | - | - | 105,000 | call | Halozyme Therapeutics Inc. | - | 52,409 % | 0,302 | -0,022 | 5,575 | 18.12.2026 | 0,100 | Morgan Stanley | |
| MM8H8S | | Halozyme Therapeutics Inc./OS/Call [105]/MS | - | - | 105,000 | call | Halozyme Therapeutics Inc. | - | 51,150 % | 0,425 | -0,017 | 3,643 | 17.06.2027 | 0,100 | Morgan Stanley | |
| MM8H8R | | Halozyme Therapeutics Inc./OS/Call [105]/MS | - | - | 105,000 | call | Halozyme Therapeutics Inc. | - | 66,224 % | 0,212 | -0,035 | 7,650 | 18.09.2026 | 0,100 | Morgan Stanley | |
| MM3GSL | | Halozyme Therapeutics Inc./OS/Call [110]/MS | - | - | 110,000 | call | Halozyme Therapeutics Inc. | - | 51,506 % | 0,390 | -0,016 | 3,743 | 17.06.2027 | 0,100 | Morgan Stanley | |
| MM3GSN | | Halozyme Therapeutics Inc./OS/Call [110]/MS | - | - | 110,000 | call | Halozyme Therapeutics Inc. | - | 54,526 % | 0,265 | -0,021 | 5,606 | 18.12.2026 | 0,100 | Morgan Stanley | |
| MN2Z3E | | Halozyme Therapeutics Inc./OS/Call [110]/MS | - | - | 110,000 | call | Halozyme Therapeutics Inc. | - | - | - | - | - | 17.12.2027 | 0,100 | Morgan Stanley | |
| MN2Z3F | | Halozyme Therapeutics Inc./OS/Call [110]/MS | - | - | 110,000 | call | Halozyme Therapeutics Inc. | - | 72,447 % | 0,193 | -0,036 | 7,243 | 18.09.2026 | 0,100 | Morgan Stanley | |
| MR3CU9 | | Halozyme Therapeutics Inc./OS/Call [110]/MS | - | - | 110,000 | call | Halozyme Therapeutics Inc. | - | 51,825 % | 0,335 | -0,018 | 4,458 | 19.03.2027 | 0,100 | Morgan Stanley | |
| MM35ZV | | Halozyme Therapeutics Inc./OS/Call [120]/MS | - | - | 120,000 | call | Halozyme Therapeutics Inc. | - | 59,289 % | 0,221 | -0,020 | 5,492 | 18.12.2026 | 0,100 | Morgan Stanley | |
| MN2Z3G | | Halozyme Therapeutics Inc./OS/Call [120]/MS | - | - | 120,000 | call | Halozyme Therapeutics Inc. | - | 84,565 % | 0,167 | -0,038 | 6,552 | 18.09.2026 | 0,100 | Morgan Stanley | |
| MR3CUA | | Halozyme Therapeutics Inc./OS/Call [120]/MS | - | - | 120,000 | call | Halozyme Therapeutics Inc. | - | 54,298 % | 0,278 | -0,017 | 4,545 | 19.03.2027 | 0,100 | Morgan Stanley | |
| MR3CUC | | Halozyme Therapeutics Inc./OS/Call [120]/MS | - | - | 120,000 | call | Halozyme Therapeutics Inc. | - | 58,504 % | 0,451 | -0,015 | 2,750 | 17.12.2027 | 0,100 | Morgan Stanley | |
| MR3CUB | | Halozyme Therapeutics Inc./OS/Call [120]/MS | - | - | 120,000 | call | Halozyme Therapeutics Inc. | - | 52,920 % | 0,333 | -0,016 | 3,867 | 17.06.2027 | 0,100 | Morgan Stanley | |
| MN5CM3 | | Halozyme Therapeutics Inc./OS/Call [60]/MS | - | - | 60,000 | call | Halozyme Therapeutics Inc. | - | - | - | - | - | 17.06.2027 | 0,100 | Morgan Stanley | |
| MN5CM4 | | Halozyme Therapeutics Inc./OS/Call [60]/MS | - | - | 60,000 | call | Halozyme Therapeutics Inc. | - | 66,260 % | 0,839 | -0,021 | 2,591 | 18.12.2026 | 0,100 | Morgan Stanley | |
| MN5CM2 | | Halozyme Therapeutics Inc./OS/Call [60]/MS | - | - | 60,000 | call | Halozyme Therapeutics Inc. | - | 88,233 % | 0,863 | -0,038 | 2,866 | 18.09.2026 | 0,100 | Morgan Stanley | |
| MN6DYC | | Halozyme Therapeutics Inc./OS/Call [60]/MS | - | - | 60,000 | call | Halozyme Therapeutics Inc. | - | - | - | - | - | 19.03.2027 | 0,100 | Morgan Stanley | |
| MN6PTH | | Halozyme Therapeutics Inc./OS/Call [60]/MS | - | - | 60,000 | call | Halozyme Therapeutics Inc. | - | - | - | - | - | 17.12.2027 | 0,100 | Morgan Stanley | |
| JE0YPB | Halozyme Therapeutics Inc./OS/Call [62]/JPMD | - | - | 62,000 | call | Halozyme Therapeutics Inc. | - | 69,673 % | 0,814 | -0,024 | 2,596 | 18.12.2026 | 0,100 | JP Morgan | ||
| JE111J | Halozyme Therapeutics Inc./OS/Call [64]/JPMD | - | - | 64,000 | call | Halozyme Therapeutics Inc. | - | 59,727 % | 0,814 | -0,021 | 2,902 | 18.12.2026 | 0,100 | JP Morgan | ||
| MM26NX | | Halozyme Therapeutics Inc./OS/Call [65]/MS | - | - | 65,000 | call | Halozyme Therapeutics Inc. | - | - | - | - | - | 17.06.2027 | 0,100 | Morgan Stanley | |
| MM26NY | | Halozyme Therapeutics Inc./OS/Call [65]/MS | - | - | 65,000 | call | Halozyme Therapeutics Inc. | - | 60,439 % | 0,800 | -0,022 | 2,935 | 18.12.2026 | 0,100 | Morgan Stanley | |
| MM5J5W | | Halozyme Therapeutics Inc./OS/Call [65]/MS | - | - | 65,000 | call | Halozyme Therapeutics Inc. | - | 65,421 % | 0,856 | -0,031 | 3,653 | 18.09.2026 | 0,100 | Morgan Stanley | |
| MN501N | | Halozyme Therapeutics Inc./OS/Call [65]/MS | - | - | 65,000 | call | Halozyme Therapeutics Inc. | - | - | - | - | - | 17.12.2027 | 0,100 | Morgan Stanley | |
| MN6DYD | | Halozyme Therapeutics Inc./OS/Call [65]/MS | - | - | 65,000 | call | Halozyme Therapeutics Inc. | - | - | - | - | - | 19.03.2027 | 0,100 | Morgan Stanley | |
| JE1HNE | Halozyme Therapeutics Inc./OS/Call [66]/JPMD | - | - | 66,000 | call | Halozyme Therapeutics Inc. | - | 67,246 % | 0,837 | -0,034 | 3,698 | 18.09.2026 | 0,100 | JP Morgan | ||
| JE0YPC | Halozyme Therapeutics Inc./OS/Call [66]/JPMD | - | - | 66,000 | call | Halozyme Therapeutics Inc. | - | 58,741 % | 0,792 | -0,022 | 3,030 | 18.12.2026 | 0,100 | JP Morgan | ||
| JE12B7 | Halozyme Therapeutics Inc./OS/Call [68]/JPMD | - | - | 68,000 | call | Halozyme Therapeutics Inc. | - | 64,691 % | 0,814 | -0,035 | 3,960 | 18.09.2026 | 0,100 | JP Morgan | ||
| JE111K | Halozyme Therapeutics Inc./OS/Call [68]/JPMD | - | - | 68,000 | call | Halozyme Therapeutics Inc. | - | 58,705 % | 0,770 | -0,023 | 3,120 | 18.12.2026 | 0,100 | JP Morgan | ||
| JE1QEA | Halozyme Therapeutics Inc./OS/Call [70]/JPMD | - | - | 70,000 | call | Halozyme Therapeutics Inc. | - | 53,358 % | 0,817 | -0,030 | 4,613 | 18.09.2026 | 0,100 | JP Morgan | ||
| JE111H | Halozyme Therapeutics Inc./OS/Call [70]/JPMD | - | - | 70,000 | call | Halozyme Therapeutics Inc. | - | 55,831 % | 0,753 | -0,023 | 3,315 | 18.12.2026 | 0,100 | JP Morgan | ||
| MM26NZ | | Halozyme Therapeutics Inc./OS/Call [70]/MS | - | - | 70,000 | call | Halozyme Therapeutics Inc. | - | 56,041 % | 0,750 | -0,023 | 3,316 | 18.12.2026 | 0,100 | Morgan Stanley | |
| MM26P0 | | Halozyme Therapeutics Inc./OS/Call [70]/MS | - | - | 70,000 | call | Halozyme Therapeutics Inc. | - | 57,473 % | 0,738 | -0,017 | 2,476 | 17.06.2027 | 0,100 | Morgan Stanley | |
| MM5J5X | | Halozyme Therapeutics Inc./OS/Call [70]/MS | - | - | 70,000 | call | Halozyme Therapeutics Inc. | - | 42,810 % | 0,857 | -0,022 | 5,187 | 18.09.2026 | 0,100 | Morgan Stanley | |
| MN030W | | Halozyme Therapeutics Inc./OS/Call [70]/MS | - | - | 70,000 | call | Halozyme Therapeutics Inc. | - | - | - | - | - | 17.12.2027 | 0,100 | Morgan Stanley | |
| MN6DYE | | Halozyme Therapeutics Inc./OS/Call [70]/MS | - | - | 70,000 | call | Halozyme Therapeutics Inc. | - | 55,940 % | 0,739 | -0,019 | 2,817 | 19.03.2027 | 0,100 | Morgan Stanley | |
| JE12AY | Halozyme Therapeutics Inc./OS/Call [72]/JPMD | - | - | 72,000 | call | Halozyme Therapeutics Inc. | - | 51,989 % | 0,784 | -0,032 | 4,967 | 18.09.2026 | 0,100 | JP Morgan | ||
| JE0YP8 | Halozyme Therapeutics Inc./OS/Call [72]/JPMD | - | - | 72,000 | call | Halozyme Therapeutics Inc. | - | 55,183 % | 0,725 | -0,024 | 3,460 | 18.12.2026 | 0,100 | JP Morgan | ||
| JZ9X22 | Halozyme Therapeutics Inc./OS/Call [74]/JPMD | - | - | 74,000 | call | Halozyme Therapeutics Inc. | - | 52,610 % | 0,737 | -0,035 | 5,254 | 18.09.2026 | 0,100 | JP Morgan | ||
| JE111N | Halozyme Therapeutics Inc./OS/Call [74]/JPMD | - | - | 74,000 | call | Halozyme Therapeutics Inc. | - | 55,037 % | 0,697 | -0,024 | 3,583 | 18.12.2026 | 0,100 | JP Morgan | ||
| MM26P1 | | Halozyme Therapeutics Inc./OS/Call [75]/MS | - | - | 75,000 | call | Halozyme Therapeutics Inc. | - | 55,210 % | 0,695 | -0,017 | 2,666 | 17.06.2027 | 0,100 | Morgan Stanley | |
| MM26P2 | | Halozyme Therapeutics Inc./OS/Call [75]/MS | - | - | 75,000 | call | Halozyme Therapeutics Inc. | - | 52,546 % | 0,688 | -0,024 | 3,755 | 18.12.2026 | 0,100 | Morgan Stanley | |
| MM5J5Y | | Halozyme Therapeutics Inc./OS/Call [75]/MS | - | - | 75,000 | call | Halozyme Therapeutics Inc. | - | 50,219 % | 0,721 | -0,035 | 5,583 | 18.09.2026 | 0,100 | Morgan Stanley | |
| MN030X | | Halozyme Therapeutics Inc./OS/Call [75]/MS | - | - | 75,000 | call | Halozyme Therapeutics Inc. | - | 63,641 % | 0,716 | -0,015 | 2,065 | 17.12.2027 | 0,100 | Morgan Stanley |